

1 **Durable SARS-CoV-2 B cell immunity after mild or severe disease**

2 Clinton O. Ogega¹, Nicole E. Skinner¹, Paul W. Blair¹, Han-Sol Park², Kirsten Littlefield²,
3 Abhinaya Ganesan², Pranay Ladiwala³, Annukka AR Antar¹, Stuart C. Ray¹, Michael J.
4 Betenbaugh³, Andrew Pekosz², Sabra L. Klein², Yukari C. Manabe¹, Andrea L. Cox^{1,2}, and
5 Justin R. Bailey^{1*}

6 **Affiliations:**

7 ¹Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of
8 Medicine, Baltimore, Maryland, USA.

9 ²W. Harry Feinstone Department of Molecular Microbiology and Immunology, The Johns
10 Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.

11 ³Advanced Mammalian Biomanufacturing Innovation Center, Department of Chemical and
12 Biomolecular Engineering, Johns Hopkins University, Baltimore, Maryland, USA.

13

14 **Key words:** SARS-CoV-2, COVID-19, neutralizing antibody, memory B cell

15 ***Address correspondence to:**

16 Justin R. Bailey, MD, PhD
17 855 N. Wolfe Street
18 Rangos Building, Suite 520
19 Baltimore MD 21205, USA
20 Phone: 410-614-6087
21 Email: jbailey7@jhmi.edu

22

23 **Conflict of interest statement.** The authors declare that they have no conflicts of interest.

24 **Abstract**

25 Multiple studies have shown loss of SARS-CoV-2 specific antibodies over time after infection,
26 raising concern that humoral immunity against the virus is not durable. If immunity wanes
27 quickly, millions of people may be at risk for reinfection after recovery from COVID-19.
28 However, memory B cells (MBC) could provide durable humoral immunity even if serum
29 neutralizing antibody titers decline. We performed multi-dimensional flow cytometric analysis of
30 S protein receptor binding domain (S-RBD)-specific MBC in cohorts of ambulatory COVID-19
31 patients with mild disease, and hospitalized patients with moderate to severe disease, at a median
32 of 54 (39-104) days after onset of symptoms. We detected S-RBD-specific class-switched MBC
33 in 13 out of 14 participants, including 4 of the 5 participants with lowest plasma levels of anti-S-
34 RBD IgG and neutralizing antibodies. Resting MBC (rMBC) made up the largest proportion of
35 S-RBD-specific class-switched MBC in both cohorts. FCRL5, a marker of functional memory
36 when expressed on rMBC, was dramatically upregulated on S-RBD-specific rMBC. These data
37 indicate that most SARS-CoV-2-infected individuals develop S-RBD-specific, class-switched
38 MBC that phenotypically resemble germinal center-derived B cells induced by effective
39 vaccination against other pathogens, providing evidence for durable B cell-mediated immunity
40 against SARS-CoV-2 after recovery from mild or severe COVID-19 disease.

41

42 **Introduction**

43 We are in the midst of an ongoing global pandemic caused by a novel coronavirus, SARS-CoV-
44 2. COVID-19, the disease caused by SARS-CoV-2, can cause pulmonary inflammation, acute
45 respiratory distress syndrome (ARDS), respiratory failure, and death. Despite the high morbidity
46 and mortality caused by COVID-19, the majority of SARS-CoV-2-infected individuals recover
47 and survive (1, 2). Following recovery, the durability of immunity against SARS-CoV-2 remains
48 unclear. Durability of immunity is critical to mitigate the risk of reinfection for millions of
49 people who have recovered or will recover from COVID-19.

50
51 After clearance of an infection or effective vaccination, phenotypically distinct B cell
52 populations contribute to short- and long-term humoral immunity. Short-lived antibody-secreting
53 cells (ASC) in blood and secondary lymphoid organs release antibodies into the circulation for
54 weeks to months. Durable humoral immunity (lasting months to years) is mediated by bone
55 marrow-resident, long-lived ASC and by memory B cells (MBC), which rapidly proliferate and
56 differentiate into ASC in response to antigen re-challenge. Multiple studies have now
57 demonstrated that serum antibody titers against SARS-CoV-2 wane and can even become
58 undetectable after resolution of infection (3-6), likely reflecting a decline in short-lived ASC
59 populations over time. Although other emerging reports have demonstrated more durable serum
60 antibody responses (7-10), concerns remain that individuals who have recovered from COVID-
61 19 may not maintain adequate immunity against reinfection. Individuals with mild COVID-19
62 disease generally mount lower titer antibody responses against the virus than those with severe
63 disease (3, 10), raising particular concern that those who recover from mild infection are not
64 protected against reinfection. If present and functional, MBC could provide durable humoral

65 immunity even after the loss of detectable serum antibody titers, as has been demonstrated after
66 vaccination against viruses like hepatitis B virus (11, 12). However, Kaneko et al. showed a
67 dramatic loss of germinal centers during acute COVID-19, raising concern that T cell dependent,
68 durable, class-switched SARS-CoV-2-specific MBC responses may not reliably develop after
69 SARS-CoV-2 infection (13).

70
71 Little is known about the frequency and phenotype of SARS-CoV-2-specific MBC that develop
72 in response to either severe or mild infection. B cells specific for the SARS-CoV-2 Spike (S)
73 protein have been isolated from individuals with very low antibody titers, but the relatively low
74 frequency of these cells has thus far limited further characterization (14). We developed a highly
75 sensitive and specific flow cytometry-based assay to quantitate circulating SARS-CoV-2 S
76 protein receptor binding domain (S-RBD)-specific B cells, and a cell surface phenotyping panel
77 to characterize these cells. We focused on S-RBD-specific B cells because most virus-
78 neutralizing human monoclonal antibodies target this domain (14-18). Neutralizing activity has
79 been associated with protection against reinfection by other coronaviruses (19-22), and
80 protection against challenge in animal models of SARS-CoV-2 infection (23, 24). Therefore, S-
81 RBD-specific B cells are likely to be the cells responsible for production of protective
82 neutralizing antibodies upon re-exposure.

83
84 Classical markers applied to these S-RBD-specific B cells allowed us to identify B cell lineages
85 including non-class-switched B cells, class-switched ASC, class-switched resting (classical)
86 MBC (rMBC), activated MBC (actMBC), atypical MBC (atyMBC), and intermediate MBC
87 (intMBC). Additional subpopulations were identified by staining for a chemokine receptor

88 (CXCR5), and potential inhibitory or activating receptors (FCRL5, CD22, and BTLA). Among
89 the cell surface regulatory molecules, FCRL5 expression is of particular interest, since its
90 expression on atyMBC has been associated with B cell dysfunction in chronic infections like
91 HIV-1 and hepatitis C virus (25). In contrast, it is also upregulated on long-lived antigen-specific
92 rMBC that develop after effective vaccination against influenza and tetanus (26, 27). This
93 FCRL5+ rMBC population preferentially expands and forms plasmablasts on antigen re-challenge,
94 indicating that FCRL5 expression on antigen-specific rMBC is a marker of effective long-lived
95 B cell-mediated immunity.

96
97 To investigate the potential for durable B cell immunity after SARS-CoV-2 infection, we
98 analyzed S-RBD-specific B cells in ambulatory COVID-19 patients with mild disease and
99 hospitalized patients with moderate to severe disease. We detected S-RBD-specific non-class-
100 switched B cells, S-RBD-specific class-switched ASC, and/or S-RBD-specific class-switched
101 MBC in all participants, regardless of their serum antibody titers or disease severity. We
102 analyzed the frequencies of these S-RBD-specific B cell populations, and of S-RBD-specific
103 MBC subsets, including rMBC, intMBC, actMBC, and atyMBC. By also quantifying cell surface
104 molecules CD38, FCRL5, CD22, BTLA, and CXCR5 on these MBC populations and subsets,
105 we identified a phenotypic profile of S-RBD-specific class switched MBC that was consistent
106 with functional, durable B cell immunity.

107

108

109 **Results**

110 **Selection of study participants.**

111 B cells were obtained from participants with mild COVID-19 disease, moderate to severe
112 disease, and from healthy COVID-19 negative controls (Table 1). Participants with mild
113 COVID-19 disease who never required hospitalization or supplemental oxygen were identified in
114 a previously described cohort of ambulatory patients (28). Symptoms in this cohort were tracked
115 using a FLU-PRO score calculated from a participant survey, as previously described (28). To
116 ensure that participants with mild disease were included in this study, a group of seven
117 participants was selected with a median peak FLU-PRO score below the median peak score for
118 the entire ambulatory cohort (FLU-PRO median (range)=0.09 (0.0-0.38) vs. 0.25 (0.0-1.63)).
119 Seven additional participants with moderate to severe COVID-19 disease were selected from a
120 second cohort of hospitalized patients (29), matched with the mild disease participants based on
121 time since onset of symptoms at the time of blood sampling (median (range) time since symptom
122 onset in days: ambulatory=61 (45-68); hospitalized=46 (39-104)). Peak supplemental oxygen
123 support in hospitalized participants ranged from 2L via nasal cannula to mechanical ventilation.
124 At the time of blood sampling for this study, five of the hospitalized participants had been
125 discharged, and two remained hospitalized with critical illness. Hereafter, ambulatory,
126 hospitalized, and healthy groups will be referred to as “mild”, “severe”, and “healthy”,
127 respectively.

128 **Quantitation of S-RBD-specific B cells.**

129 A flow cytometry antibody panel was designed to identify non-class switched B cells (CD3-,
130 CD19+, IgD/IgM+), class switched memory B cells (MBC) (CD3-, CD19+, IgM-, IgD-,

131 CD38+/- (excluding ++), CD138-) and class switched antibody secreting cells (ASC) (CD3-,
132 CD27+, CD19+/-, IgM-, IgD-, CD38++) (Supp. Figure 1). The frequency of all non-class
133 switched B cells, class switched MBC, or class switched ASC among single viable lymphocytes
134 was not significantly different between healthy, mild, and severe groups, but there was a trend
135 toward greater frequency of class-switched ASC in the severe group compared to mild and
136 healthy groups (Figure 1A). As we defined these three B cell populations, we used a 6x-histidine
137 tagged, soluble S-RBD protein followed by anti-His Alexa Fluor 647-conjugated antibody to
138 stain cells expressing S-RBD-specific antibodies on their surface (Figure 1B and Supplemental
139 Figure 1). We quantitated the frequency of these S-RBD-specific cells among non-class switched
140 B cells, class switched ASC, and class switched MBC (Figure 1C). Four of seven (57%) mild
141 and seven of seven (100%) severe participants had a frequency of S-RBD-specific non-class
142 switched B cells above the true positive threshold set using the healthy group. The frequency of
143 these cells did not differ significantly between the mild and severe groups. Four of seven (57%)
144 mild and four of seven (57%) severe participants had a frequency of S-RBD-specific class
145 switched ASC above the true positive threshold. The frequency of these cells also did not differ
146 significantly between the mild and severe groups. Six of seven (86%) mild and seven of seven
147 (100%) severe participants had a frequency of S-RBD-specific class switched MBC above the
148 true positive threshold. The single individual without detectable S-RBD-specific class switched
149 MBC was asymptomatic throughout infection (peak FLU-PRO=0.0). Frequency of S-RBD-
150 specific class switched MBC was significantly higher in severe participants than in mild
151 participants (mean S-RBD+ frequency 0.85% vs. 0.20%, $p=0.004$). Taken together, these data
152 demonstrate that S-RBD-specific cells could be detected among non-class switched B cells and
153 class switched ASC in most SARS-CoV-2-infected participants, and S-RBD-specific class

154 switched MBC could be detected in thirteen of fourteen participants. S-RBD-specific cells were
155 significantly more frequent among class switched MBC from the severe group relative to the
156 mild group.

157 **Detectable S-RBD-specific MBC despite low levels of anti-S-RBD IgG and neutralizing**
158 **antibodies in plasma.**

159 Given concerns that low or waning plasma titers of neutralizing antibodies in some individuals
160 indicate a lack of a durable humoral response, we were interested in evaluating whether COVID-
161 19 participants with low levels of plasma anti-S-RBD IgG and low neutralizing antibody levels
162 had detectable S-RBD-specific MBC in circulation. S-RBD binding IgG was measured using
163 serial dilutions of plasma in an ELISA, and neutralizing antibodies were measured with serial
164 dilutions of plasma in a microneutralization assay using replication competent SARS-CoV-2
165 virus (10). Curves were fit to these data, and area under the curve (AUC) values calculated. Anti-
166 S-RBD IgG and neutralization AUC values each varied over a wide range across study subjects
167 ($1e2.7$ - $1e4.9$ and $1e0.8$ - $1e3.0$, respectively). As expected based on prior studies (3, 10), there
168 was a trend toward higher anti-S-RBD IgG and neutralization AUC values in the severe group
169 relative to the mild group, although these differences were not statistically significant, likely due
170 to the small number of subjects (Figure 2A-B). We next evaluated whether we could detect S-
171 RBD-specific cells among class switched MBC of participants with low, intermediate, or high
172 levels of plasma anti-S-RBD IgG (Figure 2C) or low, intermediate, or high levels of neutralizing
173 antibodies (Figure 2D). We detected S-RBD-specific class switched MBC above the nonspecific
174 background frequency in 4 of 5 participants with the lowest IgG and neutralization AUCs, 5 of 5
175 with intermediate AUCs, and 4 of 4 with highest AUCs. The single individual without detectable
176 S-RBD-specific class switched MBC had the lowest levels of plasma anti-S-RBD IgG

177 (AUC=1e2.7) and neutralizing antibodies (AUC=1e0.8) in the study. There was a non-significant
178 trend toward higher frequencies of RBD specific cells among class switched MBC in the higher
179 AUC IgG and higher neutralizing antibody AUC groups relative to the lowest AUC groups.
180 Overall, these data show that S-RBD-specific class switched MBC were detectable in the
181 circulation of most infected individuals, including the majority of subjects with low levels of
182 plasma anti-S-RBD IgG and neutralizing antibodies.

183 **UMAP analysis of class switched MBC surface markers.**

184 To further characterize the phenotypes of S-RBD-specific and nonspecific class switched MBC
185 in healthy, mild, or severe COVID-19 patients, we studied surface expression of CD21, CD27,
186 FCRL5, CXCR5, CD22, BTLA, and CD38. CD21 and CD27 expression allow separation of
187 MBC into intermediate MBC (intMBC, CD21+ CD27-), resting MBC (rMBC, CD21+, CD27+),
188 activated MBC (actMBC, CD21- CD27+), and atypical MBC (atyMBC, CD21- CD27-) subsets.
189 B- and T- lymphocyte attenuator (BTLA) or CD272 and CD22/Siglec2 are immune cell
190 inhibitory receptors with cytoplasmic immunoreceptor tyrosine-based inhibition motifs (ITIMs)
191 (30-33), while FCRL5 has two ITIMs and one immunoreceptor tyrosine-based activation motif
192 (ITAM) (34, 35). C-C chemokine receptor type 5 (CXCR5) is a germinal center homing receptor
193 that is generally down-regulated after cells have undergone class switching and somatic
194 hypermutation (36, 37). CD38 has relatively undefined functional significance, but it is negative
195 on “late” class-switched MBC and positive on “early” class switched MBC that emerged more
196 recently from germinal center reactions (38).

197 We first analyzed a UMAP projection of all class switched MBC from healthy, mild, and severe
198 groups generated based on binding of S-RBD and expression of CD21, CD27, CD38, CD22,
199 FCRL5, CXCR5, and BTLA (Figure 3A). This UMAP identified a clear segregation of co-

200 mingled mild and severe S-RBD+ cells from RBD- and healthy donor cells. From this UMAP
201 clustering projection, we extrapolated multigraph color mapping of the receptors with observed
202 differential expression of all surface markers except BTLA (Figure 3B). To determine whether
203 there was any shift in expression of these markers between study groups, we overlaid
204 expression histograms of all the surface receptors of healthy, mild S-RBD-, mild S-RBD+,
205 severe S-RBD-, and severe S-RBD+ class switched MBC (Figure 3C). Again, there was no
206 observable shift in the expression of BTLA. For all study groups, there was a bimodal
207 distribution of CD21 expression, indicating that both CD21+ (intMBC and rMBC) and CD21-
208 (actMBC and atyMBC) MBC subsets were present. For both mild and severe S-RBD+ MBC, we
209 observed a shift toward increased expression of CD22 and FCRL5 and downregulation of
210 CXCR5 compared to healthy and S-RBD- populations. For CD38, we observed upregulation in
211 mild and severe S-RBD+ MBC and downregulation in mild and severe S-RBD- MBC compared
212 to healthy participants.

213 **Quantifying subsets of S-RBD nonspecific and S-RBD-specific class switched MBC**

214 To better understand the functional phenotypes of the S-RBD-specific MBC identified in both
215 mild and severe groups, we compared the frequencies of intMBC, rMBC, actMBC, and atyMBC
216 among S-RBD-specific and S-RBD nonspecific class switched MBC at the level of individual
217 participants (Figure 4). MBC subsets identified based on CD21 and CD27 expression have
218 notably different phenotypes (38). Classical MBC, also called rMBC, persist for months to years
219 and respond to antigen re-challenge by proliferating and differentiating into antibody-producing
220 ASC. ActMBC are cells that recently left germinal centers and are already primed to become
221 antibody secreting plasma cells (39). AtyMBC are generally thought to be poorly functional, and
222 are present at higher frequencies in chronic infections like HIV-1, hepatitis C virus, tuberculosis,

223 or malaria (25, 40, 41). AtyMBC were also found to be more frequent among bulk (not antigen
224 specific) MBC during acute SARS-CoV-2 infection (42). IntMBC likely represent a transitional
225 state between MBC subsets.

226 S-RBD-specific class switched MBC from two participants were not included in these or
227 subsequent analyses, either because they did not have detectable S-RBD-specific class switched
228 MBC frequency above background (subject M5), or because absolute cell numbers were low
229 given severe lymphopenia (subject S3). S-RBD nonspecific MBC were adequately abundant in
230 all participants to allow their inclusion in all analyses (see Methods). There were no statistically
231 significant differences in the frequencies of intMBC, rMBC, or atyMBC subsets among S-RBD-
232 specific or S-RBD nonspecific class switched MBC from healthy, mild or severe participants
233 (Figure 4). In contrast, actMBC were significantly more frequent among both S-RBD
234 nonspecific and S-RBD-specific MBC populations in severe participants compared to healthy
235 and mild participants (e.g. mean frequency of severe S-RBD+ MBC vs. healthy S-RBD- MBC,
236 16.09% vs. 5.53%, $p=0.01$) (Figure 4C). This likely represents greater ongoing immune
237 activation in the severe infection group relative to the healthy and mild groups and is also
238 consistent with the observed trend toward higher frequency of ASC in the severe group (Figure
239 1A). Overall, these data demonstrate an expected distribution of S-RBD-specific cells among
240 MBC subsets, with the largest proportion of S-RBD-specific class switched MBC in both mild
241 and severe groups falling in the rMBC subset.

242 **Expression of activating or inhibitory surface markers on class switched MBC and MBC** 243 **subsets.**

244 To further investigate the differential expression of surface markers that we observed in the
245 UMAP projections and histograms of grouped samples, we compared expression of FCRL5,

246 CXCR5, CD22, and CD38 at the level of individual participants between healthy, mild S-RBD-,
247 mild S-RBD+, severe S-RBD-, and severe S-RBD+ groups (Figure 5). BTLA expression was not
248 included in this analysis given no differential expression in the UMAP. We found that FCRL5
249 was dramatically upregulated in mild S-RBD+ MBC relative to healthy cells, mild S-RBD- cells,
250 and severe S-RBD+ cells ($p < 0.0001$, 0.003, and 0.01, respectively). FCRL5 was also
251 upregulated to a lesser, but still significant extent on severe S-RBD+, mild S-RBD-, and severe
252 S-RBD- MBC relative to healthy MBC ($p = 0.01$, 0.03, and 0.04, respectively) (Figure 5A). The
253 frequency of CXCR5+ cells among class switched MBC was not significantly different between
254 the groups, although it was downregulated in 3 of 6 participants in both mild and severe groups
255 (Figure 5B) which could account for the shift observed in the histogram in Figure 3C. Since
256 CD22/siglec-2 is ubiquitously expressed on B cells, we analyzed its relative expression by
257 comparing mean fluorescence intensities (MFI). Compared to healthy controls, CD22 was
258 upregulated on mild S-RBD+ class switched MBC ($p = 0.04$) (Figure 5C). Among class switched
259 MBC, CD38 expression did not differ significantly between SARS-CoV-2 infected and healthy
260 participants (Figure 5D).

261 Having observed upregulation of both FCRL5 and CD22, a trend toward downregulation of
262 CXCR5, and a trend toward upregulation of CD38 on S-RBD+ class switched MBC, we
263 analyzed expression of these surface markers on MBC subsets rMBC, intMBC, actMBC, and
264 atyMBC (Figure 6). As with total class switched RBD+ MBC, we found that FCRL5 was
265 dramatically upregulated on mild S-RBD+ rMBC relative to healthy rMBC, mild S-RBD-
266 rMBC, and severe S-RBD+ rMBC ($p < 0.0001$, < 0.0001 , and < 0.0001 , respectively). FCRL5
267 was also upregulated to a lesser, but still significant extent on severe S-RBD+ and mild S-RBD-
268 rMBC relative to healthy rMBC ($p = 0.02$ and 0.01, respectively). CXCR5 was significantly

269 downregulated on mild S-RBD+ atyMBC relative to healthy atyMBC, mild S-RBD- atyMBC,
270 and severe S-RBD+ atyMBC (p=0.001, 0.003, and 0.001, respectively). CD22 was significantly
271 upregulated on mild S-RBD+ rMBC and intMBC relative to healthy cells (p=0.02 and 0.03,
272 respectively). CD38+ cells were significantly more frequent among mild S-RBD+ actMBC
273 relative to healthy actMBC and mild S-RBD- actMBC (p=0.007 and 0.01, respectively). Taken
274 together, these results indicate that FCRL5 was significantly upregulated on S-RBD-specific
275 rMBC in both mild and severe infection. In mild but not severe infection, CD22 was upregulated
276 on S-RBD-specific rMBC and intMBC, CXCR5 was downregulated on S-RBD-specific
277 atyMBC, and CD38 was upregulated on S-RBD-specific actMBC.

278

279 Discussion

280 To investigate the durability of B cell immunity after SARS-CoV-2 infection, we
281 analyzed S-RBD-specific B cells in ambulatory COVID-19 patients with mild disease and
282 hospitalized patients with moderate to severe disease, at a median of 54 days after onset of
283 symptoms. We detected S-RBD-specific class-switched MBC in 13 out of 14 participants,
284 including 4 of the 5 participants with lowest plasma levels of anti-S-RBD IgG and neutralizing
285 antibodies. The largest proportion of S-RBD-specific class-switched MBC in both cohorts were
286 rMBC. AtymBC, which tend to be poorly functional, were a minor population. FCRL5 was
287 upregulated on S-RBD-specific rMBC after severe infection, and upregulated even more
288 dramatically after mild infection.

289 These findings are of particular interest given the observation of Kaneko et al. of a
290 dramatic loss of germinal centers in lymph nodes and spleens after SARS-CoV-2 infection (13).
291 This observation would suggest that SARS-CoV-2-specific B cells in infected individuals lack T
292 cell help and would therefore have reduced capacity to undergo class switching and transition to
293 a resting memory phenotype. Our data indicate that despite this loss of germinal centers, T cell
294 help is adequate to facilitate class switching of S-RBD-specific B cells, and transition of many of
295 these cells to a resting state, regardless of disease severity. We did not measure the extent of
296 somatic hypermutation of these B cells, but multiple groups have already demonstrated that
297 human S-RBD-specific antibodies acquire enough somatic mutations to achieve very high
298 affinity (14-18), again demonstrating that T cell help is adequate in most individuals.

299 A prior study by Oliviero et al. of bulk (not antigen-specific) MBC subsets during acute
300 or convalescent COVID-19 found that atymBC were expanded during acute infection, with
301 atymBC frequencies normalizing during convalescence (42). Our study extends that evaluation

302 by studying both S-RBD-specific and S-RBD nonspecific MBC. We found that S-RBD-specific
303 and S-RBD nonspecific atyMBC frequencies did not differ significantly from healthy controls,
304 but S-RBD-specific actMBC were expanded in severely infected individuals. The contrast of our
305 results with those of Oliviero et al. likely arise from differing timing after infection, and also by
306 our focus on antigen-specific MBC. The fact that atyMBC make up a small minority of S-RBD-
307 specific MBC provides further evidence that most S-RBD-specific MBC are normally functional.

308 It is interesting that the single individual without detectable S-RBD-specific class
309 switched MBC was asymptomatic throughout infection, and also had the lowest levels of anti-S-
310 RBD IgG and neutralizing antibodies in the study. It is possible that those with asymptomatic
311 disease, who tend to develop lower neutralizing antibody titers, may also develop lower
312 frequencies of class switched RBD-specific MBC. Given the low frequency of RBD specific
313 MBC across the cohort, we would need to analyze a larger number of PBMC to confirm with
314 confidence that this individual is truly negative for S-RBD-specific class switched MBC.

315 A limitation of this study is the lack of long-term longitudinal sampling of B cells after
316 infection, which would be required to prove that the S-RBD-specific MBC responses observed
317 here are truly durable. These studies will be pursued as longitudinal samples become available.
318 However, we have shown here that S-RBD-specific MBC in most infected individuals have a
319 phenotype that very closely resembles the phenotype of germinal center-derived MBC induced
320 by effective vaccination against influenza and tetanus. Of particular note is the upregulation of
321 FCRL5 on S-RBD-specific class switched rMBC after either mild or severe disease. FCRL5 is
322 expressed by most germinal center-derived MBC in plasmodium-infected mice, and these
323 FCRL5+ MBC differentiate into ASC on re-challenge (26). In addition, Kim et al. found that in
324 humans, presumably vaccinated against tetanus months to years prior, FCRL5 was upregulated

325 on tetanus specific rMBC (CD21+, CD27+) but not on bulk rMBC (26). Nellore et al. showed
326 similar results after influenza vaccination of humans, demonstrating that hemagglutinin (HA)-
327 specific, FCRL5+ MBC were induced by vaccination, and that these FCRL5+ MBC
328 preferentially differentiated into plasmablasts upon antigen rechallenge approximately a year
329 after vaccination (27). Further studies will be necessary to understand the implications of CD22
330 upregulation on S-RBD-specific rMBC and intMBC, CXCR5 downregulation on S-RBD-
331 specific atyMBC, and CD38 upregulation on S-RBD-specific actMBC in the mild group but not
332 the severe group, but none of these differences necessarily indicate dysfunction in either group.
333 Overall, despite our lack of longitudinal testing, the phenotypic similarity of S-RBD-specific
334 MBC in this study to typical, germinal center-derived MBC induced by effective vaccination
335 provide strong evidence that these S-RBD-specific MBC are durable and functional.

336 In summary, we have demonstrated that S-RBD-specific class-switched MBC develop in
337 most SARS-CoV-2-infected individuals, including those with mild disease or low levels of
338 plasma anti-S-RBD IgG and neutralizing antibodies. The most abundant subset of S-RBD-
339 specific class-switched MBC in both cohorts were rMBC, and atyMBC were a minor population.
340 FCRL5, a marker of a functional memory response when expressed on antigen-specific rMBC,
341 was dramatically upregulated on S-RBD-specific rMBC, particularly after mild infection. These
342 data indicate that most SARS-CoV-2-infected individuals develop S-RBD-specific, class-
343 switched MBC that phenotypically resemble B cells induced by effective vaccination against
344 other pathogens, providing evidence for durable humoral immunity against SARS-CoV-2 after
345 recovery from either mild or severe COVID-19 disease. These data have implications for risk of
346 reinfection after recovery from COVID-19, and also provide a standard against which B cell
347 responses to novel SARS-CoV-2 vaccines could be compared.

348 **Methods**

349 **Study participants**

350 Participants with mild COVID-19 disease who never required hospitalization or supplemental
351 oxygen were identified in a cohort of ambulatory COVID-19 patients. Symptoms in this cohort
352 were tracked using a FLU-PRO score calculated from a participant survey, as previously
353 described (28). Participants with moderate to severe COVID-19 disease were selected from a
354 cohort of hospitalized patients (29), matched with the mild participants based on time since onset
355 of symptoms at the time of blood sampling. PBMC cryopreserved prior to the onset of the
356 COVID-19 pandemic were also obtained from anonymous healthy blood donors. Healthy and
357 COVID-19 participant blood specimens were ficoll gradient separated into plasma and PBMCs.
358 PBMCs were viably cryopreserved in FBS + 10% DMSO for future use.

359 **Expression and purification of soluble Spike protein Receptor Binding Domain (S-RBD)**

360 Plasmid preparation

361 Recombinant plasmid constructs containing modified S protein Receptor Binding Domain (S-
362 RBD) and a beta-lactamase (amp) gene were obtained (Stadlbauer 2020) and amplified in E.coli
363 after transformation and growth on LB agar plates coated with Ampicillin. The plasmids were
364 extracted using GigaPrep kits (Thermo Fisher Scientific) and eluted in molecular biology grade
365 water.

366 Recombinant protein expression

367 HEK293.2sus cells (ATCC) were obtained and adapted to Freestyle™ F-17 medium (Thermo
368 Fisher Scientific) and BalanCD® (Irvine Scientific) using polycarbonate shake flasks

369 (Fisherbrand) with 4mM GlutaMAX supplementation (Thermo Fisher Scientific). The cells were
370 routinely maintained every 4 days at a seeding density of 0.5 million cells/mL. They were
371 cultured at 37°C, 90% humidity with 5% CO₂ for cells in BalanCD® while those in F-17 were
372 maintained at 8% CO₂. Cells were counted using trypan blue dye (Gibco) exclusion method and
373 a hemocytometer. Cell viability was always maintained above 90%. Twenty-four hours prior to
374 transfection (Day -1), the cells were seeded at a density of 1 million cells/mL, ensuring that the
375 cell viability was above 90%. Polyethylenimine (PEI) stocks, with 25 kDa molecular mass
376 (Polysciences), were prepared in MilliQ water at a concentration of 1 mg/mL. This was filter
377 sterilized through a 0.22 µm syringe filter (Corning), aliquoted and stored at -20°C. On the day
378 of transfection (Day 0), the cells were counted to ensure sufficient growth and viability.
379 OptiPRO™ SFM (Gibco) was used as the medium for transfection mixture. For 100 mL of cell
380 culture, 2 tubes were aliquoted with 6.7 mL each of OptiPRO™, one for PEI and the other for
381 rDNA. DNA:PEI ratio of 1:3.5 was used for transfection. A volume of 350 µL of prepared PEI
382 stock solution was added to tube 1 while 100 µg of rDNA was added to tube 2 and incubated for
383 5 minutes. Post incubation, these were mixed together, incubated for 10 minutes at RT and then
384 added to the culture through gravity addition. The cells were returned back to the 37°C
385 incubator. A day after transfection (Day 1), the cells were spun down at 1,000 rpm for 7 minutes
386 at RT and resuspended in fresh media with GlutaMAX™ supplementation. 3-5 hours after
387 resuspension, 0.22 µm sterile filtered Sodium butyrate (EMD Millipore) was added to the flask at
388 a final concentration of 5 mM (Grünberg et al.). The cells were allowed to grow for a period of
389 4-5 days. Cell counts, viability, glucose and lactate values were measured every day. Cells were
390 harvested when either the viability fell below 60% or when the glucose was depleted, by
391 centrifugation at 5000 rpm for 10 minutes at RT. Cell culture supernatants containing either

392 recombinant S-RBD or S protein were filtered through 0.22 μm PES membrane stericup filters
393 (Millipore Sigma) to remove cell debris and stored at -20°C until purification.

394 Protein purification

395 Protein purification by immobilized metal affinity chromatography (IMAC) and gravity flow
396 was adapted from previous methods (23). After washing with Phosphate-Buffered Saline (PBS;
397 Thermo Fisher Scientific), Nickel-Nitrilotriacetic acid (Ni-NTA) agarose (Qiagen) was added to
398 culture supernatant followed by overnight incubation (12-16 hours) at 4°C on a rotator. For
399 every 150 mL of culture supernatant, 2.5 mL of Ni-NTA agarose was added. 5mL gravity flow
400 polypropylene columns (Qiagen) were equilibrated with PBS. One polypropylene column was
401 used for every 150 mL of culture supernatant. The supernatant-agarose mixture was then loaded
402 onto the column to retain the agarose beads with recombinant proteins bound to the beads. Each
403 column was then washed, first with 1X culture supernatant volume of PBS and then with 25 mL
404 of 20 mM imidazole (Millipore Sigma) in PBS wash buffer to remove host cell proteins.

405 Recombinant proteins were then eluted from each column in three fractions with 5 mL of 250
406 mM imidazole in PBS elution buffer per fraction giving a total of 15 mL eluate per column. The
407 eluate was subsequently dialyzed several times against PBS using Amicon Ultra Centrifugal
408 Filters (Millipore Sigma) at 7000 rpm for 20 minutes at 10°C to remove the imidazole and
409 concentrate the eluate. Filters with a 10 kDa molecular weight cut-off were used for S-RBD
410 eluate. The final concentration of the recombinant S-RBD and S proteins was measured by
411 bicinchoninic acid (BCA) assay (Thermo Fisher Scientific), and purity was assessed on 10%
412 SDS-PAGE (Bio-Rad) followed by Coomassie blue staining. After sufficient destaining in water
413 overnight, clear single bands were visible for S-RBD.

414 Viruses and cells.

415 Vero-E6 cells (ATCC CRL-1586) and Vero-E6-TMPRSS2 cells (24) were cultured in
416 Dulbecco's modified Eagle medium (DMEMD) containing 10% fetal bovine serum (Gibco), 1
417 mM glutamine (Invitrogen), 1 mM sodium pyruvate (Invitrogen), 100 U/ml of penicillin
418 (Invitrogen), and 100 µg/ml of streptomycin (Invitrogen) (complete media or CM). Cells were
419 incubated in a 5% CO₂ humidified incubator at 37°C. The SARS-CoV-2/USA-WA1/2020 virus
420 was obtained from BEI Resources. The infectious virus titer was determined on Vero cells using
421 a 50% tissue culture infectious dose (TCID₅₀) assay as previously described for SARS-CoV (25,
422 26). Serial 10-fold dilutions of the virus stock were made in infection media (IM, which is
423 identical to CM except the FBS is reduced to 2.5%), then then 100 µl of each dilution was added
424 to Vero cells in a 96-well plate in sextuplicate. The cells were incubated at 37°C for 4 days,
425 visualized by staining with naphthol blue-black, and scored visually for cytopathic effect. A
426 Reed and Muench calculation was used to determine TCID₅₀ per ml (27).

427 **Measurement of endpoint anti-S-RBD IgG titer.**

428 The protocol was adapted from a published protocol from Dr. Florian Krammer's laboratory
429 (Stadlbauer 2020). Ninety-six well plates (Immulon 4HBX, Thermo Fisher) were coated with S-
430 RBD at a volume of 50 µl of 2 µg/ml of diluted antigen in filtered, sterile 1xPBS (Thermo
431 Fisher) at 4°C overnight. Coating buffer was removed, plates were washed three times with 300
432 µl of PBS-T wash buffer (1xPBS plus 0.1% Tween 20, Fisher Scientific), and blocked with 200
433 µl of PBS-T with 3% non-fat milk (milk powder, American Bio) by volume for one hour at room
434 temperature. All plasma samples were heat inactivated at 56°C on a heating block for one hour
435 prior to use. Negative control samples were prepared at 1:10 dilutions in PBS-T in 1% non-fat
436 milk and plated at a final concentration of 1:100. A monoclonal antibody (mAb) specific for the

437 SARS-CoV-2 spike protein was used as a positive control (1:5,000, Sino Biological). For serial
438 dilutions of plasma on S-RBD coated plates, plasma samples were prepared in three-fold serial
439 dilutions starting at 1:20 in PBST in 1% non-fat-milk. Blocking solution was removed and 10 μ l
440 of diluted plasma was added in duplicates to plates and incubated at room temperature for two
441 hours. Plates were washed three times with PBS-T wash buffer and 50 μ l secondary antibody
442 was added to plates and incubated at room temperature for one hour. Anti-human secondary
443 antibodies used included Fc-specific total IgG HRP (1:5,000 dilution, Invitrogen), prepared in
444 PBS-T plus 1% non-fat milk. Plates were washed and all residual liquid removed before adding
445 100 μ l of SIGMAFAST OPD (o-phenylenediamine dihydrochloride) solution (Sigma Aldrich) to
446 each well, followed by incubation in darkness at room temperature for ten minutes. To stop the
447 reaction, 50 μ l of 3M hydrochloric acid (HCl, Fisher Scientific) was added to each well. The OD
448 of each plate was read at 490nm (OD490) on a SpectraMax i3 ELISA plate reader (BioTek). The
449 positive cutoff value for each plate was calculated by summing the average of the negative
450 values and three times the standard deviation of the negatives. All values at or above the cutoff
451 value were considered positive. Values were graphed on a dose response curve, a best fit line
452 drawn by nonlinear regression, and area under the curve (AUC) calculated.

453 **Measurement of endpoint neutralization titer.**

454 Plasma neutralization titers were determined as described for SARS-CoV (Schaecher 2008).
455 Two-fold dilutions of plasma (starting at a 1:20 dilution) were made in IM. Infectious virus was
456 added to the plasma dilutions at a final concentration of 1×10^4 TCID₅₀/ml (100 TCID₅₀ per
457 100 μ l). The samples were incubated for one hour at room temperature, then 100 μ l of each
458 dilution was added to one well of a 96 well plate of VeroE6-TMPRSS2 cells in sextuplet for 6
459 hours at 37°C. The inoculums were removed, fresh IM was added, and the plates were incubated

460 at 37°C for 2 days. The cells were fixed by the addition of 150 uL of 4% formaldehyde per well,
461 incubated for at least 4 hours at room temperature, then stained with Naphthol blue black. The
462 nAb titer was calculated as the highest serum dilution that eliminated cytopathic effect (CPE) in
463 50% of the wells. Values were graphed on a dose response curve, a best fit line drawn by
464 nonlinear regression, and area under the curve (AUC) calculated.

465 **Cell staining and flow cytometry**

466 PBMCs were isolated from blood using ficoll separation gradient and viably frozen. Cells were
467 thawed before use, and 5e6-10e6 PBMCs were stained from each participant. Fc blocker (BD
468 Cat #564220) diluted in FACS Buffer (1x PBS with 1% BSA) was added to the cells and
469 incubated for 30minutes on ice or 4c. The cells were then washed twice with FACS buffer.
470 Soluble 6X-His tagged S-RBD protein was then added to the cells and incubated at room
471 temperature for 30 min. This was followed by wash steps with FACS buffer. Conjugated
472 antibodies (Suppl. Table 1 for list of antibodies and their conjugate fluorophores) and live dead
473 stain was then added to the cells and incubated for an additional 30min. The cells were washed
474 two or three more times before running the cells on BD Biosciences LSR II instrument. 1e6-6e6
475 total events were collected for each participant, resulting in medians of 69.5 absolute RBD+ and
476 13,971 RBD- class switched MBC for each participant (range=1-454 RBD+, 152-84,645 RBD-
477 MBC). For UMAP analysis, all RBD+ class switched MBC were included, and RBD- class
478 switched MBC were downsampled to 3000 cells per subject. The subject with only 1 RBD+ cell
479 was excluded from RBD+ MBC subset analyses. Positive gates for each fluorophore were set
480 after compensation and using fluorescence minus one (FMO) staining and isotype control
481 antibodies.

482 **Statistical analysis**

483 FlowJo software was used to analyze all the flow results from the LSRII. Statistical analyses
484 were performed in Prism (Graphpad software). Two group comparisons were performed with t
485 tests if data were normally distributed based on Shapiro Wilk normality test or Mann Whitney
486 rank test if data were not normally distributed. Multi-group comparisons were performed using
487 one-way ANOVA, with p values adjusted for multiple comparisons using the Benjamini, Krieger
488 and Yekutieli method.

489 **Study approval.**

490 This research was approved by the Johns Hopkins University School of Medicine's Institutional
491 Review Board (IRB). Prior to blood collection, all participants provided informed written
492 consent.

493

494

495

496 **Author Contributions.** COO conceived the project, performed experiments, interpreted data,
497 and wrote the initial manuscript draft; NES conceived the project, performed experiments, and
498 interpreted data; PWB interpreted data; HSP, KL, and AG performed experiments and
499 interpreted data; AA interpreted data; SCR interpreted data; PL and MJB provided reagents. AP
500 performed experiments and interpreted data; SLK performed experiments and interpreted data;
501 YCM conceived the project and provided participant samples; ALC conceived the project,
502 provided participant samples, and interpreted data; JRB conceived the project, interpreted data,
503 and wrote the initial manuscript draft. All authors reviewed and edited the manuscript.

504 **Acknowledgements.** We would like to thank participants in the study, Florian Krammer for
505 providing the S-RBD plasmid, and members of the Johns Hopkins Viral Hepatitis Center for
506 thoughtful discussion. We thank the Bloomberg Flow Cytometry and Immunology Core for
507 equipment and technical assistance. We thank the National Institute of Infectious Diseases,
508 Japan, for providing VeroE6TMPRSS2 cells and acknowledge the Centers for Disease Control
509 and Prevention, BEI Resources, NIAID, NIH for SARS-related coronavirus 2, isolate USA-
510 WA1/2020, NR-5228. This research was supported by the National Institutes of Health grants
511 R01AI127469 and R21AI151353 (to J.R.B.), U54CA260492 (SLK and AC), and in part by the
512 NIH Center of Excellence for Influenza Research and Surveillance (HHSN272201400007C, to
513 AP and SLK)..

514

515 References

- 516 1. Guan WJ, and Zhong NS. Clinical Characteristics of Covid-19 in China. Reply. *N Engl J*
517 *Med.* 2020;382(19):1861-2.
- 518 2. Wang Z, Yang B, Li Q, Wen L, and Zhang R. Clinical Features of 69 Cases With
519 Coronavirus Disease 2019 in Wuhan, China. *Clin Infect Dis.* 2020;71(15):769-77.
- 520 3. Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, Liao P, Qiu JF, Lin Y, Cai XF,
521 et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. *Nat Med.* 2020.
- 522 4. Seow J, Graham C, Merrick B, Acors S, Steel KJA, Hemmings O, O'Bryne A, Kouphou
523 N, Pickering S, Galao R, et al. Longitudinal evaluation and decline of antibody responses
524 in SARS-CoV-2 infection. *medRxiv.* 2020:2020.07.09.20148429.
- 525 5. Ibarondo FJ, Fulcher JA, Goodman-Meza D, Elliott J, Hofmann C, Hausner MA, Ferbas
526 KG, Tobin NH, Aldrovandi GM, and Yang OO. Rapid Decay of Anti-SARS-CoV-2
527 Antibodies in Persons with Mild Covid-19. *N Engl J Med.* 2020;383(11):1085-7.
- 528 6. Patel MM, Thornburg NJ, Stubblefield WB, Talbot HK, Coughlin MM, Feldstein LR,
529 and Self WH. Change in Antibodies to SARS-CoV-2 Over 60 Days Among Health Care
530 Personnel in Nashville, Tennessee. *JAMA.* 2020.
- 531 7. Wajnberg A, Amanat F, Firpo A, Altman D, Bailey M, Mansour M, McMahon M, Meade
532 P, Mendu DR, Muellers K, et al. SARS-CoV-2 infection induces robust, neutralizing
533 antibody responses that are stable for at least three months. *medRxiv.*
534 2020:2020.07.14.20151126.
- 535 8. Isho B, Abe KT, Zuo M, Jamal AJ, Rathod B, Wang JH, Li Z, Chao G, Rojas OL, Bang
536 YM, et al. Persistence of serum and saliva antibody responses to SARS-CoV-2 spike
537 antigens in COVID-19 patients. *Sci Immunol.* 2020;5(52).
- 538 9. Iyer AS, Jones FK, Nodoushani A, Kelly M, Becker M, Slater D, Mills R, Teng E,
539 Kamruzzaman M, Garcia-Beltran WF, et al. Persistence and decay of human antibody
540 responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19
541 patients. *Sci Immunol.* 2020;5(52).
- 542 10. Klein SL, Pekosz A, Park HS, Ursin RL, Shapiro JR, Benner SE, Littlefield K, Kumar S,
543 Naik HM, Betenbaugh MJ, et al. Sex, age, and hospitalization drive antibody responses in
544 a COVID-19 convalescent plasma donor population. *J Clin Invest.* 2020.
- 545 11. Salimzadeh L, Le Bert N, Dutertre CA, Gill US, Newell EW, Frey C, Hung M, Novikov
546 N, Fletcher S, Kennedy PT, et al. PD-1 blockade partially recovers dysfunctional virus-
547 specific B cells in chronic hepatitis B infection. *J Clin Invest.* 2018;128(10):4573-87.
- 548 12. Middleman AB, Baker CJ, Kozinetz CA, Kamili S, Nguyen C, Hu DJ, and Spradling PR.
549 Duration of protection after infant hepatitis B vaccination series. *Pediatrics.*
550 2014;133(6):e1500-7.
- 551 13. Kaneko N, Kuo HH, Boucau J, Farmer JR, Allard-Chamard H, Mahajan VS, Piechocka-
552 Trocha A, Lefteri K, Osborn M, Bals J, et al. Loss of Bcl-6-Expressing T Follicular
553 Helper Cells and Germinal Centers in COVID-19. *Cell.* 2020;183(1):143-57 e13.
- 554 14. Robbiani DF, Gaebler C, Muecksch F, Lorenzi JCC, Wang Z, Cho A, Agudelo M,
555 Barnes CO, Gazumyan A, Finkin S, et al. Convergent antibody responses to SARS-CoV-
556 2 in convalescent individuals. *Nature.* 2020;584(7821):437-42.
- 557 15. Zost SJ, Gilchuk P, Case JB, Binshtein E, Chen RE, Nkolola JP, Schafer A, Reidy JX,
558 Trivette A, Nargi RS, et al. Potently neutralizing and protective human antibodies against
559 SARS-CoV-2. *Nature.* 2020;584(7821):443-9.

- 560 16. Noy-Porat T, Makdasi E, Alcalay R, Mechaly A, Levy Y, Bercovich-Kinori A,
561 Zauberman A, Tamir H, Yahalom-Ronen Y, Israeli M, et al. A panel of human
562 neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. *Nat Commun.*
563 2020;11(1):4303.
- 564 17. Rogers TF, Zhao F, Huang D, Beutler N, Burns A, He WT, Limbo O, Smith C, Song G,
565 Woehl J, et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection
566 from disease in a small animal model. *Science.* 2020;369(6506):956-63.
- 567 18. Brouwer PJM, Caniels TG, van der Straten K, Snitselaar JL, Aldon Y, Bangaru S, Torres
568 JL, Okba NMA, Claireaux M, Kerster G, et al. Potent neutralizing antibodies from
569 COVID-19 patients define multiple targets of vulnerability. *Science.*
570 2020;369(6504):643-50.
- 571 19. Buchholz UJ, Bukreyev A, Yang L, Lamirande EW, Murphy BR, Subbarao K, and
572 Collins PL. Contributions of the structural proteins of severe acute respiratory syndrome
573 coronavirus to protective immunity. *Proc Natl Acad Sci U S A.* 2004;101(26):9804-9.
- 574 20. Du L, He Y, Zhou Y, Liu S, Zheng BJ, and Jiang S. The spike protein of SARS-CoV--a
575 target for vaccine and therapeutic development. *Nat Rev Microbiol.* 2009;7(3):226-36.
- 576 21. Li T, Xie J, He Y, Fan H, Baril L, Qiu Z, Han Y, Xu W, Zhang W, You H, et al. Long-
577 term persistence of robust antibody and cytotoxic T cell responses in recovered patients
578 infected with SARS coronavirus. *PLoS One.* 2006;1(e24).
- 579 22. Huang AT, Garcia-Carreras B, Hitchings MDT, Yang B, Katzelnick L, Rattigan SM,
580 Borgert B, Moreno C, Solomon BD, Rodriguez-Barraquer I, et al. A systematic review of
581 antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection,
582 and association of antibody responses with severity of disease. *medRxiv.*
583 2020:2020.04.14.20065771.
- 584 23. Deng W, Bao L, Liu J, Xiao C, Liu J, Xue J, Lv Q, Qi F, Gao H, Yu P, et al. Primary
585 exposure to SARS-CoV-2 protects against reinfection in rhesus macaques. *Science.*
586 2020;369(6505):818-23.
- 587 24. Chandrashekar A, Liu J, Martinot AJ, McMahan K, Mercado NB, Peter L, Tostanoski
588 LH, Yu J, Maliga Z, Nekorchuk M, et al. SARS-CoV-2 infection protects against
589 rechallenge in rhesus macaques. *Science.* 2020;369(6505):812-7.
- 590 25. Moir S, Ho J, Malaspina A, Wang W, DiPoto AC, O'Shea MA, Roby G, Kottlilil S,
591 Arthos J, Proschan MA, et al. Evidence for HIV-associated B cell exhaustion in a
592 dysfunctional memory B cell compartment in HIV-infected viremic individuals. *J Exp*
593 *Med.* 2008;205(8):1797-805.
- 594 26. Kim CC, Baccarella AM, Bayat A, Pepper M, and Fontana MF. FCRL5(+) Memory B
595 Cells Exhibit Robust Recall Responses. *Cell Rep.* 2019;27(5):1446-60 e4.
- 596 27. Nellore A, Scharer CD, King RG, Tipton CM, Zumaquero E, Fucile C, Mousseau B,
597 Bradley JE, Macon K, Mi T, et al. Fcrl5 and T-bet define influenza-specific memory B
598 cells that predict long-lived antibody responses. *bioRxiv.* 2019:643973.
- 599 28. Blair PW, Brown DM, Jang M, Antar AA, Keruly JC, Bachu V, Townsend JL, Tornheim
600 JA, Keller SC, Sauer L, et al. The clinical course of COVID-19 in the outpatient setting: a
601 prospective cohort study. *medRxiv.* 2020:2020.09.01.20184937.
- 602 29. Thompson EA, Cascino K, Ordonez AA, Zhou W, Vaghasia A, Hamacher-Brady A,
603 Brady NR, Sun I-H, Wang R, Rosenberg AZ, et al. Metabolic programs define
604 dysfunctional immune responses in severe COVID-19 patients. *medRxiv.*
605 2020:2020.09.10.20186064.

- 606 30. Crocker PR, Paulson JC, and Varki A. Siglecs and their roles in the immune system.
607 *Nature Reviews Immunology*. 2007;7(4):255-66.
- 608 31. Macauley MS, Crocker PR, and Paulson JC. Siglec-mediated regulation of immune cell
609 function in disease. *Nature Reviews Immunology*. 2014;14(10):653-66.
- 610 32. Tateno H, Li H, Schur MJ, Bovin N, Crocker PR, Wakarchuk WW, and Paulson JC.
611 Distinct endocytic mechanisms of CD22 (Siglec-2) and Siglec-F reflect roles in cell
612 signaling and innate immunity. *Mol Cell Biol*. 2007;27(16):5699-710.
- 613 33. Watanabe N, Gavrieli M, Sedy JR, Yang J, Fallarino F, Loftin SK, Hurchla MA,
614 Zimmerman N, Sim J, Zang X, et al. BTLA is a lymphocyte inhibitory receptor with
615 similarities to CTLA-4 and PD-1. *Nat Immunol*. 2003;4(6):70-9.
- 616 34. Davis RS. FCRL regulation in innate-like B cells. *Ann N Y Acad Sci*. 2015;1362(1):110-
617 6.
- 618 35. Liao HX, Lynch R, Zhou T, Gao F, Alam SM, Boyd SD, Fire AZ, Roskin KM, Schramm
619 CA, Zhang Z, et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder
620 virus. *Nature*. 2013;496(7446):469-76.
- 621 36. Hardtke S, Ohl L, and Förster R. Balanced expression of CXCR5 and CCR7 on follicular
622 T helper cells determines their transient positioning to lymph node follicles and is
623 essential for efficient B-cell help. *Blood*. 2005;106(6):1924-31.
- 624 37. Junt T, Fink K, Förster R, Senn B, Lipp M, Muramatsu M, Zinkernagel RM, Ludewig B,
625 and Hengartner H. CXCR5-Dependent Seeding of Follicular Niches by B and Th Cells
626 Augments Antiviral B Cell Responses. *The Journal of Immunology*. 2005;175(11):7109-
627 16.
- 628 38. Sanz I, Wei C, Lee FE, and Anolik J. Phenotypic and functional heterogeneity of human
629 memory B cells. *Semin Immunol*. 2008;20(1):67-82.
- 630 39. Lau D, Lan LY, Andrews SF, Henry C, Rojas KT, Neu KE, Huang M, Huang Y,
631 DeKosky B, Palm AE, et al. Low CD21 expression defines a population of recent
632 germinal center graduates primed for plasma cell differentiation. *Sci Immunol*. 2017;2(7).
- 633 40. Joosten SA, van Meijgaarden KE, Del Nonno F, Baiocchi A, Petrone L, Vanini V,
634 Smits HH, Palmieri F, Goletti D, and Ottenhoff TH. Patients with Tuberculosis Have a
635 Dysfunctional Circulating B-Cell Compartment, Which Normalizes following Successful
636 Treatment. *PLoS Pathog*. 2016;12(6):e1005687.
- 637 41. Portugal S, Tipton CM, Sohn H, Kone Y, Wang J, Li S, Skinner J, Virtaneva K,
638 Sturdevant DE, Porcella SF, et al. Malaria-associated atypical memory B cells exhibit
639 markedly reduced B cell receptor signaling and effector function. *Elife*. 2015;4(
- 640 42. Oliviero B, Varchetta S, Mele D, Mantovani S, Cerino A, Perotti CG, Ludovisi S, and
641 Mondelli MU. Expansion of atypical memory B cells is a prominent feature of COVID-
642 19. *Cell Mol Immunol*. 2020;17(10):1101-3.

Graphical Abstract




Table 1. Participant characteristics

Participant ID	Age ¹	Sex	Race	Ethnicity	Days from symptom onset	FLU-PRO ²	Supp. O ₂ ³
Mild-ambulatory							
M1	60	F	White	Non-Hispanic	63	0.38	none
M2	50	F	Hawaiian/Pacific Islander	Non-Hispanic	68	0.28	none
M3	60	F	White	Hispanic	59	0.19	none
M4	70	F	White	Non-Hispanic	64	0.06	none
M5	60	M	White	Non-Hispanic	46	0	none
M6	40	M	Black	Non-Hispanic	61	0.03	none
M7	30	M	American Indian/Alaska Native	Non-Hispanic	45	0.09	none
<i>median</i>	<i>60</i>				<i>61</i>	<i>0.09</i>	
Severe-hospitalized							
S1	70	F	Black	Non-Hispanic	90	n/a	4LNC
S2	50	M	Black	Non-Hispanic	104	n/a	HFNC
S3	60	M	White	Non-Hispanic	48	n/a	Intubated
S4	50	M	Other	Non-Hispanic	46	n/a	2LNC
S5	80	F	Black	Non-Hispanic	39	n/a	Intubated
S6	50	M	Black	Non-Hispanic	42	n/a	HFNC
S7	70	M	Other	Non-Hispanic	41	n/a	Intubated
<i>median</i>	<i>60</i>				<i>46</i>		

¹Age rounded to nearest 10 to avoid identifying participants. ²Peak FLU-PRO score. ³Maximum oxygen support required. 4LNC, 4 liters via nasal cannula; HFNC, high flow oxygen via nasal cannula; intubated, requiring mechanical ventilation; 2LNC, 2 liters via nasal cannula.




Figure 1. Quantifying S-RBD specific B cells. (A) % of lymphocytes that are class switched MBC, class switched ASC, or non-class switched B cells in healthy, mild, and severe participants (N=7 for each group). **(B)** Gating strategy for S-RBD specific non-class switched B cells (CD3⁻, CD19⁺, IgD/IgM⁺, S-RBD⁺), S-RBD specific class switched MBC (CD3⁻, CD19⁺, IgM⁻, IgD⁻, CD38^{+/-} (excluding ++), CD138⁻, S-RBD⁺), and S-RBD specific class switched ASC (CD3⁻, CD19^{+/-}, IgM⁻, IgD⁻, CD38⁺⁺, CD27⁺, S-RBD⁺) in “healthy” (COVID-19 negative), “mild” (COVID-19+, ambulatory), and “severe” (COVID-19+, hospitalized) participants. **(C)** % of class switched MBC, class switched ASC, and non-class switched B cells that are S-RBD specific in healthy, mild, and severe participants (N=7 for each group). Dotted line represents the true positive threshold, defined as the mean plus two standard deviations of the healthy group. For **A** and **C** box plots, horizontal lines indicate means, boxes are inter-quartile range, and whiskers are minimum to maximum. Three group comparisons in **A** were performed using one-way ANOVA, with p values adjusted for multiple comparisons using the Benjamini, Krieger and Yekutieli method. Two group comparisons in **C** were performed with t tests if data were normally distributed based on Shapiro Wilk normality test or Mann Whitney test if data were not normally distributed. Statistically significant comparisons are indicated (** P ≤ 0.01)





Figure 2. Comparisons of serum anti S-RBD IgG and neutralizing antibody titers in mild and severe participants. (A) Anti S-RBD IgG area under the curve (AUC) in mild and severe participants. **(B)** Neutralizing antibody AUC in mild and severe participants. **(C)** % of class switched MBC that are RBD specific, from participants with plasma anti-S-RBD AUC values in the lowest, middle, and highest tertiles. **(D)** % of class switched MBC that are RBD specific, from participants with plasma neutralizing antibody AUC values in the lowest, middle, and highest tertiles. Dotted line represents the true positive threshold, defined as the mean plus two standard deviations of the healthy group. For box plots, horizontal lines indicate means, boxes are inter-quartile range, and whiskers are minimum to maximum. P values for **A-B** were calculated using t tests and P values for **C-D** were calculated using one-way ANOVA test for linear trend. No statistically significant comparison was found.






Figure 4: Frequency of MBC subsets in S-RBD nonspecific (S-RBD-) or S-RBD specific (S-RBD+) class switched MBC from healthy, mild, or severe participants. (A) intMBC (CD21+, CD27-). (B) rMBC (CD21+, CD27+). (C) actMBC (CD21-, CD27+). (D) atyMBC (CD21-, CD27-). For box plots, horizontal lines indicate means, boxes are inter-quartile range, and whiskers are minimum to maximum. Groups were compared by one-way ANOVA with p values adjusted for multiple comparisons using the Benjamini, Krieger and Yekutieli method. Statistically significant comparisons are indicated (* $P \leq 0.05$).




Figure 5: Surface expression of FcRL5, CXCR5, CD22, and CD38 on S-RBD nonspecific (S-RBD-) or S-RBD specific (S-RBD+) class switched MBC from healthy, mild, or severe participants. Expression is shown as either percent of cells positive or the mean fluorescent intensity (MFI). (A) FcRL5 (B) CXCR5 (C) CD22 (D) CD38. For box plots, horizontal lines indicate means, boxes are inter-quartile range, and whiskers are minimum to maximum. Groups were compared by one-way ANOVA with p values adjusted for multiple comparisons using the Benjamini, Krieger and Yekutieli method. Statistically significant comparisons are indicated (* P ≤ 0.05, ** P ≤ 0.01, * P ≤ 0.001, **** P ≤ 0.0001).**




Figure 6: Surface expression of FcRL5, CXCR5, CD22, and CD38 on S-RBD nonspecific (S-RBD-) or S-RBD specific (S-RBD+) class switched intMBC, rMBC, actMBC, or atyMBC from healthy, mild, or severe participants. Expression is shown as either percent of cells positive or the mean fluorescent intensity (MFI). (A) FcRL5 (B) CXCR5 (C) CD22 (D) CD38. For box plots, horizontal lines indicate means, boxes are inter-quartile range, and whiskers are minimum to maximum. Groups were compared by one-way ANOVA with p values adjusted for multiple comparisons using the Benjamini, Krieger and Yekutieli method. Statistically significant comparisons are indicated (* $P \leq 0.05$, ** $P \leq 0.01$, * $P \leq 0.001$, **** $P \leq 0.0001$).**